Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Recursion Pharmaceuticals Inc Cl A (RXRX)

Recursion Pharmaceuticals Inc Cl A (RXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
A concept image showing a virus attacking blood cells by crystal light via Shutterstock
Nvidia Dumped Recursion Pharmaceuticals Stock. Should You? Barchart - Thu Feb 19, 3:47PM CST

Nvidia sold its position in Recursion Pharmaceuticals, while others keep a measured outlook. Does this divergence signal risk or opportunity?

NVDA : 189.82 (+1.02%)
RXRX : 3.42 (-8.06%)
ARKK : 71.49 (-1.04%)
MarketBeat.com
NVIDIA’s 13F Bombshell: A New AI Power Trio Emerges MarketBeat - Thu Feb 19, 10:14AM CST

NVIDIA did anything but stand pat with its investments during Q4 2025. See how the company turned over its holdings in the quarter.

NVDA : 189.82 (+1.02%)
CRWV : 89.25 (-8.12%)
INTC : 44.11 (-1.14%)
SNPS : 439.94 (-0.57%)
AMD : 200.15 (-1.58%)
WRD : 7.09 (-2.88%)
APLD : 29.04 (-7.90%)
RXRX : 3.42 (-8.06%)
NBIS : 97.92 (-9.00%)
NOK : 7.77 (+2.24%)
ARM : 125.58 (-1.06%)
AMZN : 210.11 (+2.56%)
Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25 GlobeNewswire - Wed Feb 18, 7:30AM CST

Salt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business...

RXRX : 3.42 (-8.06%)
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules GlobeNewswire - Thu Feb 12, 6:59AM CST

Salt Lake City, Utah, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026,...

RXRX : 3.42 (-8.06%)
Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Tue Jan 6, 6:59AM CST

Salt Lake City, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President,...

RXRX : 3.42 (-8.06%)
Image of Cathie Wood via Wikimedia Commons
Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? Barchart - Wed Dec 24, 2025

Cathie Wood is resolute on RXRX despite its slump. Should investors follow her lead into this AI-driven biotech bet now?

ARKG : 28.81 (-3.55%)
RXRX : 3.42 (-8.06%)
ARKK : 71.49 (-1.04%)
Platform Oncology Technologies Drive Multi-Indication Treatment Expansion BayStreet.ca - Fri Dec 12, 2025

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Artificial intelligence and platform-based approaches reshaped cancer treatment development in November...

ONCY : 0.9640 (-3.60%)
SANA : 4.01 (-3.14%)
ABSI : 2.65 (-4.68%)
RXRX : 3.42 (-8.06%)
TEM : 58.37 (-2.65%)
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks GlobeNewswire - Mon Dec 8, 2025

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12) After 12 weeks...

RXRX : 3.42 (-8.06%)
AI-Powered Platforms Accelerate Healthcare's Preventative Care Wellness Revolution BayStreet.ca - Tue Dec 2, 2025

Issued on behalf of Aleen Inc. VANCOUVER – Baystreet.ca News Commentary – The artificial intelligence in healthcare market is projected to expand from $17.2 billion in 2025 to $77.2 billion...

AIDX.TO : 0.62 (unch)
HWAIF : 0.4495 (-0.77%)
WELL.TO : 3.98 (+0.51%)
RXRX : 3.42 (-8.06%)
TEM : 58.37 (-2.65%)
WHTCF : 2.9000 (+0.69%)
ALEN-U.CN : 1.2100 (unch)
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025 GlobeNewswire - Mon Dec 1, 2025

Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a...

RXRX : 3.42 (-8.06%)

Barchart Exclusives

Most Retail Investors Think They’re Investing: They’re Actually Trading The Market Barchart - Sat Feb 21, 10:10AM CST
Most retail investors think they’re investing in businesses, but they’re actually reacting to market noise instead of analyzing incentives, capital allocation, and structural change. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot